Evidence map›Paper›PMID 24572791›Full record

ArticleGene therapy2014

Gene transfer of arginine kinase to skeletal muscle using adeno-associated virus.

S C Forbes, L T Bish, F Ye, J Spinazzola, C Baligand, D Plant, K Vandenborne, E R Barton, H L Sweeney, G A Walter

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gene therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Effects of muscle damage onNMR in biomedicine · 2022
    Article
  2. Article
  3. Gene Therapy for Heart Failure: New Perspectives.Current heart failure reports · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

S C ForbesDepartment of Physical Therapy, University of Florida, Gainesville, FL, USA.
L T BishDepartment of Physiology, University of Pennsylvania, Philadelphia, PA, USA.
F YeDepartment of Physical Therapy, University of Florida, Gainesville, FL, USA.
J SpinazzolaDepartment of Anatomy and Cell Biology, University of Pennsylvania, Philadelphia, PA, USA.
C BaligandDepartment of Physiology and Functional Genomics, University of Florida, Gainesville, FL, USA.
D PlantAdvanced Magnetic Resonance Imaging and Spectroscopy Facility, University of Florida, Gainesville, FL, USA.
K VandenborneDepartment of Physical Therapy, University of Florida, Gainesville, FL, USA.
E R BartonDepartment of Anatomy and Cell Biology, University of Pennsylvania, Philadelphia, PA, USA.
H L SweeneyDepartment of Physiology, University of Pennsylvania, Philadelphia, PA, USA.
G A WalterDepartment of Physiology and Functional Genomics, University of Florida, Gainesville, FL, USA.
University of Florida · USUniversity of Pennsylvania · US

Funding

VIRAL VECTOR DELIVERY OF ANTISENSE TO ACE MRNA IN CARDIOVASCULAR DISEASEP01HL059412 · NHLBI · UNIVERSITY OF FLORIDA · PI MUZYCZKA, NICHOLAS · 1998 to 2012
$20.2M
Therapeutic Strategies to Augment Muscle RehabilitationP01HD059751 · NICHD · UNIVERSITY OF FLORIDA · PI VANDENBORNE, KRISTA H · 2009 to 2010
$2.3M
NHLBI NIH HHS P01 HL059412NHLBI NIH HHS P01 HL59412NICHD NIH HHS P01 HD059751
6 · The paper itself

Abstract

In this study, we tested the feasibility of non-invasively measuring phosphoarginine (PArg) after gene delivery of arginine kinase (AK) using an adeno-associated virus (AAV) to murine hindlimbs. This was achieved by evaluating the time course, regional distribution and metabolic flux of PArg using (31)phosphorus magnetic resonance spectroscopy ((31)P-MRS). AK gene was injected into the gastrocnemius of the left hindlimb of C57Bl10 mice (age 5 weeks, male) using self-complementary AAV, type 2/8 with desmin promoter. Non-localized (31)P-MRS data were acquired over 9 months after injection using 11.1-T and 17.6-T Bruker Avance spectrometers. In addition, (31)P two-dimensional chemical shift imaging and saturation transfer experiments were performed to examine the spatial distribution and metabolic flux of PArg, respectively. PArg was evident in each injected mouse hindlimb after gene delivery, increased until 28 weeks, and remained elevated for at least 9 months (P<0.05). Furthermore, PArg was primarily localized to the injected posterior hindimb region and the metabolite was in exchange with ATP. Overall, the results show the viability of AAV gene transfer of AK gene to skeletal muscle, and provide support of PArg as a reporter that can be used to non-invasively monitor the transduction of genes for therapeutic interventions.

Indexed as

AnimalsArginineArginine KinaseDependovirusGenetic TherapyGenetic VectorsHindlimbMiceMuscle, SkeletalOrganophosphorus CompoundsPromoter Regions, GeneticTransduction, GeneticArginineArginine KinaseOrganophosphorus Compoundsphospho-L-arginine

Identifiers

PMID24572791
PMCPMC3975678
OpenAlexW2006653825

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.